Key result
Rivaroxaban is linked to spontaneous hemopericardium in three patients.
Why the study?
Hemopericardium has not been frequently described as an adverse bleeding effect of rivaroxaban despite reports of other bleeding complications during post-marketing surveillance.
Does rivaroxaban administration lead to spontaneous hemopericardium?
Case Report (n=3)
No
Does rivaroxaban administration lead to spontaneous hemopericardium?
This report highlights spontaneous hemopericardium as a rare but potentially severe bleeding complication of rivaroxaban therapy.
Hemopericardium may occur rarely with rivaroxaban; this report extends post-marketing surveillance data but leaves incidence and causality open.
Rivaroxaban is a direct oral anticoagulant with a favorable safety profile when compared to warfarin in respect to bleeding. During post-marketing surveillance, intracranial and retroperitoneal bleedings have been reported; however, hemopericardium has not been frequently described.
No takes yet. Share an insight, caveat, or question.
Asif et al. (2019) conducted a case report in Spontaneous hemopericardium (n=3). Rivaroxaban was evaluated on Spontaneous hemopericardium. Three patients developed spontaneous hemopericardium while receiving rivaroxaban, highlighting a potentially life-threatening adverse effect of the anticoagulant.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: